Professional background

Dr Magdalena Dziadzio is a consultant immunologist working in the Department of Specialist Allergy and Clinical Immunology primarily based at the Royal National Throat Nose and Ear Hospital. Magdalena is one of the very few specialists in the UK with dual accreditation in both Clinical Immunology and Internal Medicine. She trained in Internal Medicine in Italy, primarily in the Academic Department of Internal Medicine in Ancona. The departmental focus was on autoimmune and connective tissue diseases, haematological malignancies and immunodeficiency. She subsequently joined the UK Specialist Register and also obtained MRCP by examination. Magdalena was awarded PhD in Immunology in Italy, with work on systemic sclerosis carried out in colaboration with Professor Dame Carol Black's group at the Royal Free Hospital. She later worked as a clinical research fellow in the Academic Centre for Connective Tissue Diseases at the Royal Free Hospital.

Her passion for immunology led her to obtain FRCPath and complete specialist training in clinical immunology and allergy. She trained in immunology in the Department of Immunology and the UCL Centre for Immunity and Transplantation based at the Royal Free Hospital. She completed her allergy training at the RNTNEH and UCLH. Along the way she obtained an MSc in Medical Immunology from King’s College, London. She has an honorary appointment as UCL Senior Lecturer. She is a member of the IVIG panel for the UCLH.

Magdalena has special interests in laboratory immunology, the immune mechanisms underlying allergic diseases and primary and secondary immunodeficiencies.

She is actively involved with the British Society of immunology and is a member of the BSI Congress Committee. She is also involved in delivering specialist training in allergy and immunology.

Research interests

Primary and secondary immunodeficiencies.

Publications

Selected publications:

Yong PF*, Dziadzio M*, Grimbacher B. Defects in B cell survival and activation. Chapter in: Encyclopedia of Immunobiology, Academic Press, ISBN-13: 978-0123742797; Volume 5, (466-478). *contributed equally.

Dziadzio M, Ammann S, Canning C, Boyle F, Hassan A, Cale C, Elawad M, Gyrd-Hansen M, Fiil BK, Saltzer U, Speckmann C, Grimbacher B. Symptomatic males and female carriers in large Caucasian kindred with XIAP deficiency. J Clin Immunol 2015;35(5):439-44.

Sassi A; Lazaroski S; Gang W; Haslam S; Mellouli F, Patiroglu T, Jouhadi Z; Khadir K; Pfeifer D; Jakob T; Khemiri M; Ben-Mustapha I; Asplund C; Gustafsson MO; Lundin KE; Falk-Sörqvist E; Moens LN; Unal E; Ozdemir MA; Gungor HE; Engelhardt KR; Dziadzio M; Stauss H; Fleckenstein B; Fliegauf M; Meier R; Kraus H; Ben-Khemis L; Nadifi S; Eibel H; Nilsson M; Bejaoui M; Schäffer AA; Smith CIE; Dell A; Barbouche MR, Grimbacher B. Hypomorphic, homozygous mutations in Phosphoglucomutase-3 impair immunity and increase serum IgE levels. J Allergy Clin Immunol.2014;133(5):1410-1419.

Dziadzio M, Chee R, McNamara C, Wagner T, Deheragoda M, Seneviratne S. EBV-driven Diffuse Large B-Cell Lymphoma confined to the liver in a patient with a history of idiopathic CD4 lymphopenia. BMJ Case Rep 2013. doi:10.1136/bcr-2013-009721.

Tennent G, Dziadzio M, Triantafillidou E, Davies P, Gallimore J, Denton C, Pepys M. Normal circulating serum amyloid P component concentration in systemic sclerosis. Arthritis Rheum 2007;56(6):2013-17.

Dziadzio M, Smith R. Metaanalysis is not a substitution for a comprehensive national registry. Clin Rheumatol 2007;26(7):1134-5.

Dziadzio M, Smith R, Abraham D, Black C, Denton C. Circulating levels of active TGFβ1 are reduced in early stage dcSSc and correlate inversely with modified Rodnan skin score. Rheumatology (Oxford) 2005;44:1518-24.

Dziadzio M, Usinger B, Leask A, Abraham D, Black CM, Denton C, Stratton R. N-terminal CTGF is a marker of the fibrotic phenotype in the connective tissue disease scleroderma. QJM. 2005;89:485-92.

Dziadzio M, Smith R, Abraham D, Stratton R, Black C, Gabrielli A, Denton C. Serological assessment of type I collagen burden in scleroderma spectrum disorders: a systematic review. Clin Exp Rheumatol 2004;22(3):356-67.

Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, Black CM. Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week randomized, parallel-group controlled study. Arthritis Rheum 1999;42(12):2646-55.

GMC/GDC number: 4463513